Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross- national dementia study

Mary Ganguli, Vijay Chandra, M. Ilyas Kamboh, Janet M. Johnston, Hiroko Dodge, B. K. Thelma, Ramcsh C. Juyal, Rajesh Pandav, Steven H. Belle, Steven T. DeKosky

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

Background: The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. Objective: To compare APOE*E4-AD epidemiological associations in India and the United States in a cross- national epidemiological study. Design: Case-control design within 2 cohort studies, using standardized cognitive screening and clinical evaluation to identify AD and other dementias and polymerase chain reaction to identify APOE genotyping. Participants: Rural community samples, aged 55 years or older (n = 4450) in Ballabgarh, India, and 70 years or older (n = 886) in the Monongahela Valley region of southwestern Pennsylvania. Main Outcome Measures: Criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable and possible AD and Clinical Dementia Rating (CDR) scale for dementia staging. Results: Frequency of APOE*E4 was significantly lower (P <.001) in Ballabgarh vs the Monongahela Valley (0.07 vs 0.11). Frequency of probable or possible AD, with CDR of at least 1.0, in the Indian vs US samples, was as follows: aged 55 to 69 years, 0.1% (Indian sample only); aged 70 to 79 years, 0.7% vs 3.1%; aged 80 years or older, 4.0% vs 15.7%. Among those aged 70 years or older, adjusted odds ratios (95% confidence interval) for AD among carriers of APOE*E4 vs noncarriers were 3.4 (1.2-9.3) and 2.3 (1.3-4.0) in the Indian and US samples, respectively, and not significantly different between cohorts (P = .20). Conclusions: This first report of APOE*E4 and AD from the Indian subcontinent shows very low prevalence of AD in Ballabgarh, India, but association of APOE*E4 with AD at similar strength in Indian and US samples.

Original languageEnglish (US)
Pages (from-to)824-830
Number of pages7
JournalArchives of Neurology
Volume57
Issue number6
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Apolipoproteins E
Dementia
Alzheimer Disease
Apolipoprotein E4
India
National Institute of Neurological Disorders and Stroke
Alzheimer's Disease
Polymorphism
Communication Disorders
Rural Population
Ethnic Groups
Epidemiologic Studies
Cohort Studies
Alleles
Odds Ratio
Outcome Assessment (Health Care)
Confidence Intervals
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ganguli, M., Chandra, V., Kamboh, M. I., Johnston, J. M., Dodge, H., Thelma, B. K., ... DeKosky, S. T. (2000). Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross- national dementia study. Archives of Neurology, 57(6), 824-830.

Apolipoprotein E polymorphism and Alzheimer disease : The Indo-US cross- national dementia study. / Ganguli, Mary; Chandra, Vijay; Kamboh, M. Ilyas; Johnston, Janet M.; Dodge, Hiroko; Thelma, B. K.; Juyal, Ramcsh C.; Pandav, Rajesh; Belle, Steven H.; DeKosky, Steven T.

In: Archives of Neurology, Vol. 57, No. 6, 06.2000, p. 824-830.

Research output: Contribution to journalArticle

Ganguli, M, Chandra, V, Kamboh, MI, Johnston, JM, Dodge, H, Thelma, BK, Juyal, RC, Pandav, R, Belle, SH & DeKosky, ST 2000, 'Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross- national dementia study', Archives of Neurology, vol. 57, no. 6, pp. 824-830.
Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge H, Thelma BK et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross- national dementia study. Archives of Neurology. 2000 Jun;57(6):824-830.
Ganguli, Mary ; Chandra, Vijay ; Kamboh, M. Ilyas ; Johnston, Janet M. ; Dodge, Hiroko ; Thelma, B. K. ; Juyal, Ramcsh C. ; Pandav, Rajesh ; Belle, Steven H. ; DeKosky, Steven T. / Apolipoprotein E polymorphism and Alzheimer disease : The Indo-US cross- national dementia study. In: Archives of Neurology. 2000 ; Vol. 57, No. 6. pp. 824-830.
@article{7b73e281f7d445f5a3646cc94017220c,
title = "Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross- national dementia study",
abstract = "Background: The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. Objective: To compare APOE*E4-AD epidemiological associations in India and the United States in a cross- national epidemiological study. Design: Case-control design within 2 cohort studies, using standardized cognitive screening and clinical evaluation to identify AD and other dementias and polymerase chain reaction to identify APOE genotyping. Participants: Rural community samples, aged 55 years or older (n = 4450) in Ballabgarh, India, and 70 years or older (n = 886) in the Monongahela Valley region of southwestern Pennsylvania. Main Outcome Measures: Criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable and possible AD and Clinical Dementia Rating (CDR) scale for dementia staging. Results: Frequency of APOE*E4 was significantly lower (P <.001) in Ballabgarh vs the Monongahela Valley (0.07 vs 0.11). Frequency of probable or possible AD, with CDR of at least 1.0, in the Indian vs US samples, was as follows: aged 55 to 69 years, 0.1{\%} (Indian sample only); aged 70 to 79 years, 0.7{\%} vs 3.1{\%}; aged 80 years or older, 4.0{\%} vs 15.7{\%}. Among those aged 70 years or older, adjusted odds ratios (95{\%} confidence interval) for AD among carriers of APOE*E4 vs noncarriers were 3.4 (1.2-9.3) and 2.3 (1.3-4.0) in the Indian and US samples, respectively, and not significantly different between cohorts (P = .20). Conclusions: This first report of APOE*E4 and AD from the Indian subcontinent shows very low prevalence of AD in Ballabgarh, India, but association of APOE*E4 with AD at similar strength in Indian and US samples.",
author = "Mary Ganguli and Vijay Chandra and Kamboh, {M. Ilyas} and Johnston, {Janet M.} and Hiroko Dodge and Thelma, {B. K.} and Juyal, {Ramcsh C.} and Rajesh Pandav and Belle, {Steven H.} and DeKosky, {Steven T.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "57",
pages = "824--830",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Apolipoprotein E polymorphism and Alzheimer disease

T2 - The Indo-US cross- national dementia study

AU - Ganguli, Mary

AU - Chandra, Vijay

AU - Kamboh, M. Ilyas

AU - Johnston, Janet M.

AU - Dodge, Hiroko

AU - Thelma, B. K.

AU - Juyal, Ramcsh C.

AU - Pandav, Rajesh

AU - Belle, Steven H.

AU - DeKosky, Steven T.

PY - 2000/6

Y1 - 2000/6

N2 - Background: The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. Objective: To compare APOE*E4-AD epidemiological associations in India and the United States in a cross- national epidemiological study. Design: Case-control design within 2 cohort studies, using standardized cognitive screening and clinical evaluation to identify AD and other dementias and polymerase chain reaction to identify APOE genotyping. Participants: Rural community samples, aged 55 years or older (n = 4450) in Ballabgarh, India, and 70 years or older (n = 886) in the Monongahela Valley region of southwestern Pennsylvania. Main Outcome Measures: Criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable and possible AD and Clinical Dementia Rating (CDR) scale for dementia staging. Results: Frequency of APOE*E4 was significantly lower (P <.001) in Ballabgarh vs the Monongahela Valley (0.07 vs 0.11). Frequency of probable or possible AD, with CDR of at least 1.0, in the Indian vs US samples, was as follows: aged 55 to 69 years, 0.1% (Indian sample only); aged 70 to 79 years, 0.7% vs 3.1%; aged 80 years or older, 4.0% vs 15.7%. Among those aged 70 years or older, adjusted odds ratios (95% confidence interval) for AD among carriers of APOE*E4 vs noncarriers were 3.4 (1.2-9.3) and 2.3 (1.3-4.0) in the Indian and US samples, respectively, and not significantly different between cohorts (P = .20). Conclusions: This first report of APOE*E4 and AD from the Indian subcontinent shows very low prevalence of AD in Ballabgarh, India, but association of APOE*E4 with AD at similar strength in Indian and US samples.

AB - Background: The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. Objective: To compare APOE*E4-AD epidemiological associations in India and the United States in a cross- national epidemiological study. Design: Case-control design within 2 cohort studies, using standardized cognitive screening and clinical evaluation to identify AD and other dementias and polymerase chain reaction to identify APOE genotyping. Participants: Rural community samples, aged 55 years or older (n = 4450) in Ballabgarh, India, and 70 years or older (n = 886) in the Monongahela Valley region of southwestern Pennsylvania. Main Outcome Measures: Criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable and possible AD and Clinical Dementia Rating (CDR) scale for dementia staging. Results: Frequency of APOE*E4 was significantly lower (P <.001) in Ballabgarh vs the Monongahela Valley (0.07 vs 0.11). Frequency of probable or possible AD, with CDR of at least 1.0, in the Indian vs US samples, was as follows: aged 55 to 69 years, 0.1% (Indian sample only); aged 70 to 79 years, 0.7% vs 3.1%; aged 80 years or older, 4.0% vs 15.7%. Among those aged 70 years or older, adjusted odds ratios (95% confidence interval) for AD among carriers of APOE*E4 vs noncarriers were 3.4 (1.2-9.3) and 2.3 (1.3-4.0) in the Indian and US samples, respectively, and not significantly different between cohorts (P = .20). Conclusions: This first report of APOE*E4 and AD from the Indian subcontinent shows very low prevalence of AD in Ballabgarh, India, but association of APOE*E4 with AD at similar strength in Indian and US samples.

UR - http://www.scopus.com/inward/record.url?scp=0034096319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034096319&partnerID=8YFLogxK

M3 - Article

C2 - 10867779

AN - SCOPUS:0034096319

VL - 57

SP - 824

EP - 830

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -